Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

Imatinib Mesylate 8Sunitinib 3ripretinib 2regorafenib 2apatinib 2IDRX-42 2trastuzumab deruxtecan 1pemigatinib 1olverembatinib 1envafolimab 1atezolizumab 1Temozolomide 1Surgical Instruments 1Quality Assurance, Health Care 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Liquid Biopsy 1Dasatinib 1Blood Specimen Collection 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gastrointestinal Stromal Tumors × olverembatinib × Clear all
NCT03594422 2026-04-09

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡